{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T08:22:30Z","timestamp":1781770950146,"version":"3.54.5"},"reference-count":15,"publisher":"Japanese Society of Internal Medicine","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,12,1]]},"DOI":"10.2169\/internalmedicine.1471-22","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T22:14:16Z","timestamp":1681424056000},"page":"3455-3460","source":"Crossref","is-referenced-by-count":13,"title":["Early Effect of Calcitonin Gene-related Peptide Monoclonal Antibodies in Migraine with Medication Overuse: A Single-center Retrospective Study"],"prefix":"10.2169","volume":"62","author":[{"given":"Yasuo","family":"Ito","sequence":"first","affiliation":[{"name":"Department of Neurology, Saitama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Mitsufuji","sequence":"additional","affiliation":[{"name":"Department of Neurology, Saitama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Neurology, Saitama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shugo","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Neurology, Saitama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryu","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Department of Neurology, Saitama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kawasaki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Saitama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimasa","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Neurology, Saitama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38: 1-211, 2018.","DOI":"10.1177\/0333102417738202"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kristoffersen ES, Lundqvist C. Medication - overuse headache: epidemiology, diagnosis and treatment. Ther Adv Drug Saf 5: 87-99, 2014.","DOI":"10.1177\/2042098614522683"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Tepper SJ, Diener HC, Ashina M, et al. Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology 92: e2309-e2320, 2019.","DOI":"10.1212\/WNL.0000000000007497"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Dodick DW, Doty EG, Aurora SK, et al. Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine. Cephalalgia 41: 340-352, 2021.","DOI":"10.1177\/0333102420966658"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Silberstein SD, Cohen JM, Seminerio MJ, Yang R, Ashina S, Katsarava Z. The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study. J Headache Pain 21: 114, 2020.","DOI":"10.1186\/s10194-020-01173-8"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Russell MB. Epidemiology and management of medication-overuse headache in the general population. Neurol Sci 40: 23-26, 2019.","DOI":"10.1007\/s10072-019-03812-8"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Westergaard ML, Hansen EH, Gl\u00fcmer C, Olesen J, Jensen RH. Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review. Cephalalgia 34: 409-425, 2014.","DOI":"10.1177\/0333102413512033"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Stovner LJ, Andree C. Prevalence of headache in Europe: a review for the Eurolight project. J Headache Pain 11: 289-299, 2010.","DOI":"10.1007\/s10194-010-0217-0"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Vandenbussche N, Laterza D, Lisicki M, et al. Medication-overuse headache: a widely recognized entity amidst ongoing debate. J Headache Pain 19: 50, 2018.","DOI":"10.1186\/s10194-018-0875-x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Pijpers JA, Louter MA, de Bruin ME, et al. Detoxifcation in medication-overuse headache, a retrospective controlled follow-up study: does care by a headache nurse lead to cure? Cephalalgia 36: 122-130, 2016.","DOI":"10.1177\/0333102415583146"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Louter MA, Robbins MS, Terwindt GM. Medication overuse headache: an ongoing debate. Neurology 89: 1206-1207, 2017.","DOI":"10.1212\/WNL.0000000000004374"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Olesen J. Detoxification for medication overuse headache is the primary task. Cephalalgia 32: 420-422, 2012.","DOI":"10.1177\/0333102411431309"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sacco S, Amin FM, Ashina M, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain 23: 67, 2022.","DOI":"10.1186\/s10194-022-01431-x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Nichols R, Doty E, Sacco S, et al. Analysis of initial nonresponders to galcanezumab in patients with episodic or chronic migraine: results from the EVOLVE-1, EVOLVE-2, and REGAIN randomized, double-blind, placebo-controlled studies. Headache 59: 192-204, 2019.","DOI":"10.1111\/head.13443"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Overeem LH, Peikert A, Hofacker MD, et al. Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study. Cephalalgia 42: 291-301, 2022.","DOI":"10.1177\/03331024211048765"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/23\/62_1471-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T03:19:05Z","timestamp":1701487145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/23\/62_1471-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":15,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1471-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]},"article-number":"1471-22"}}